Adage Capital Partners
AARD

Adage Capital Partners’s Aardvark Therapeutics AARD Stock Holding History

Adage Capital Partners’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.73M Hold
300,000
– – ﹤0.01% 882
2026
Q1 		$1.13M Buy
+300,000
New +$3.11M ﹤0.01% 867
2025
Q4 		– Sell
-350,000
Closed -$4.65M – 1037
2025
Q3 		$4.65M Buy
350,000
+175,000
+100% +$1.97M 0.01% 743
2025
Q2 		$2.37M Sell
175,000
-75,000
-30% -$773K ﹤0.01% 756
2025
Q1 		$1.88M Buy
+250,000
New +$2.81M ﹤0.01% 763

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Adage Capital Partners's AARD Position: Q2 2026 in Review

Adage Capital Partners held its Aardvark Therapeutics (AARD) position steady in Q2 2026 at 300,000 shares worth $1.73M. The position accounts for ﹤0.01% of the portfolio, ranked #882.

Adage Capital Partners first reported a position in AARD in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.65M in Q3 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Adage Capital Partners held 300,000 shares of Aardvark Therapeutics worth $1.73M as of Q2 2026.
  • Adage Capital Partners left its Aardvark Therapeutics share count unchanged in Q2 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Adage Capital Partners's portfolio in Q2 2026, its #882 holding.
  • Adage Capital Partners first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Adage Capital Partners's Aardvark Therapeutics position peaked at $4.65M in Q3 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.